Xconomy’s Digital Events →
June 11, 2020 · New York
June 25, 2020 · San Francisco
October 1, 2020 · Seattle
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says... Read more »
Sponsored · Special Report
Hyperinflation in rents is over
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.